Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Synergistic efficacy and preliminary molecular mechanisms of venetoclax combined with microtransplantation in the treatment of elderly patients with Acute Myeloid Leukemia

Yuxian Huang, Yingzhi He, Jiayue Wei, Ziwei Liu, Yinjie Qin, Yeqin Zheng, Yuchang Lin, Zhiming Li, Yuhua Li

Blood (2025) 146 (Supplement 1): 7794.

https://doi.org/10.1182/blood-2025-7794

Published: 2025

Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood (2025) 146 (Supplement 1): 887.

https://doi.org/10.1182/blood-2025-887

Published: 2025

Journal Articles

Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: Updated results of the phase II study

Zhiming Li, Peng SUN, Kaiyang Ding, Gang Huang, Hang Yang, Yu Wang

Blood (2025) 146 (Supplement 1): 3639.

https://doi.org/10.1182/blood-2025-3639

Published: 2025

Journal Articles

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy

Elizabeth Budde, Jason Westin, Huilai Zhang, Dai Maruyama, Eduardo M. Rego, Huangming Hong, Hideki Goto, Mark Fesler, Boone Goodgame, Zhiming Li, Adam Olszewski, Joan Ashby, Shen Yin, Wahib S. Ead, Martin Janousek, Song Pham, Connie L. Batlevi, Michael C. Wei, Won-Seog Kim

Blood (2025) 146 (Supplement 1): 5509.

https://doi.org/10.1182/blood-2025-5509

Published: 2025

Journal Articles

First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial

Hang Yang, Peng SUN, Panpan LIU, Yu Wang, Hui Zhou, Ying Lu, Lu Zhang, Keshu Zhou, Zhiming Li

Blood (2025) 146 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2025-1922

Published: 2025

Journal Articles

Comparable survival with transplant-free approach versus autologous stem cell transplantation in adult relapsed/refractory classic Hodgkin lymphoma achieving complete remission

Panpan LIU, Caiyun Wang, Peng SUN, Hang Yang, Mengqiu Wu, Man Nie, Yu Wang, Qingqing Cai, Yi Xia, Huang He, Huiqiang Huang, Zhiming Li

Blood (2025) 146 (Supplement 1): 5397.

https://doi.org/10.1182/blood-2025-5397

Published: 2025

Journal Articles

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Shuhua Yi, Liping Su, Bingzong Li, Zhiming Li, Zhengming Jin, Ming Jiang, Wenjuan Yu, Zengjun Li, Jun Luo, Wei Yang, Fei Li, Cailing Wang, Hui Wu, Qiang Wang, Bing Yu, Jianghua Chen, June Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2025-1808

Published: 2025

Journal Articles

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Yan Huang, Yanyan Liu, Hongming He, Zhiming Li, Ningjing Lin, Ou Bai, Caixia Li, Xiaobo Wang, Yajun Li, Xingli Zhao, Huijing Wu, Xiaorui Fu, Zhihua Yao, Jiuyang Zhang, Ying Chen, Wei Meng, Zhuli Wu, Wenzhi Tian, Yuqin Song

Blood (2025) 146 (Supplement 1): 5358.

https://doi.org/10.1182/blood-2025-5358

Published: 2025

Journal Articles

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Ningjing Lin, Keshu Zhou, Quande Lin, Lihua Qiu, Zhiming Li, Wei Yang, Yuerong Shuang, Jian Zhang, Hongyan Tong, Hongmei Jing, Peiqi Zhao, Jing Liu, Hong Li, hongli zhang, Liqiang Fu, Gang Lu, Yuqin Song

Blood (2025) 146 (Supplement 1): 5368.

https://doi.org/10.1182/blood-2025-5368

Published: 2025

Journal Articles

Lung infections and clinical outcomes of diffuse large B-cell lymphoma treated with polatuzumab vedotin-based combination therapy

Ning Wang, Feili Chen, Zetao Chen, Ling Huang, Xinmiao Jiang, Xiaojuan Wei, Hanguo Guo, Sichu Liu, Zhiming Li, Wenyu Li

Blood (2025) 146 (Supplement 1): 8090.

https://doi.org/10.1182/blood-2025-8090

Published: 2025

Journal Articles

Synergistic Remission of refractory cutaneous T-cell lymphoma by linperlisib plus venetoclax via targeting the PI3K/AKT/CREB-BCL-2/MCL-1 signaling axis.

Yuxian Huang, Ziwei Liu, Jiayue Wei, Yinjie Qin, Yingzhi He, Yeqin Zheng, Yuchang Lin, Zhiming Li, Yuhua Li

Blood (2025) 146 (Supplement 1): 7177.

https://doi.org/10.1182/blood-2025-7177

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

Smart start with tislelizumab as frontline treatment in advanced‐stage classical Hodgkin lymphoma：a PET-adapted, chemotherapy-sparing phase 2 study

Yu Wang, Zeng Ruixin, Peng SUN, Hang Yang, Panpan LIU, Man Nie, Yu-Hua Huang, Zhiming Li

Blood (2025) 146 (Supplement 1): 3624.

https://doi.org/10.1182/blood-2025-3624

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in Relapsed/Refractory large B-cell lymphoma: A systematic review and meta-analysis

Ning Yuan, Fei Xu, Panpan LIU, Hang Yang, Yu Wang, Zhiming Li, Peng SUN

Blood (2025) 146 (Supplement 1): 4548.

https://doi.org/10.1182/blood-2025-4548

Published: 2025

Journal Articles

Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study

Yuqin Song, Qingsong Yin, Zhiming Li, Jingye Meng, Yan Yan, Mengli Zhou, Wenyi Sun, Kezhen Liu, Jun Zhu

Blood (2024) 144 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2024-193938

Published: 2024

Journal Articles

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Blood (2024) 144 (Supplement 1): 3120.

https://doi.org/10.1182/blood-2024-206700

Published: 2024

Journal Articles

Early Assessment of Lymphoma Therapeutic Efficacy Via a Blood-Based Multi-Omics Test

Xinhua Wang, Zhiming Li, Yu Chang, Shiyong Li, Wei Wu, Fangyuan Chang, Yinyin Chang, Dandan Zhu, Mingzhi Zhang, Mao Mao

Blood (2024) 144 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2024-202715

Published: 2024

Journal Articles

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Zhiming Li, Jun Fang, Huilai Zhang, Wei Wang, Hui Li, Hui Zhou, Liqun Zou, Hong Cen, Wen Shujuan, Wuping Li, Peng Sun, Panpan LIU, Hang Yang, Yu Wang

Blood (2024) 144 (Supplement 1): 6542.

https://doi.org/10.1182/blood-2024-204292

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Synergistic efficacy and preliminary molecular mechanisms of venetoclax combined with microtransplantation in the treatment of elderly patients with Acute Myeloid Leukemia

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: Updated results of the phase II study

First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial

Comparable survival with transplant-free approach versus autologous stem cell transplantation in adult relapsed/refractory classic Hodgkin lymphoma achieving complete remission

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Lung infections and clinical outcomes of diffuse large B-cell lymphoma treated with polatuzumab vedotin-based combination therapy

Synergistic Remission of refractory cutaneous T-cell lymphoma by linperlisib plus venetoclax via targeting the PI3K/AKT/CREB-BCL-2/MCL-1 signaling axis.

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Smart start with tislelizumab as frontline treatment in advanced‐stage classical Hodgkin lymphoma：a PET-adapted, chemotherapy-sparing phase 2 study

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in Relapsed/Refractory large B-cell lymphoma: A systematic review and meta-analysis

Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Early Assessment of Lymphoma Therapeutic Efficacy Via a Blood-Based Multi-Omics Test

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only